Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7 | Zendy

Anna Mróz | Zendy; Izabela Ryska | Zendy; Hanna Sominko | Zendy; Anna Bejrowska | Zendy; Zofia Mazerska | Zendy

Open Access

Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7

Author(s) -

Anna Mróz,

Izabela Ryska,

Hanna Sominko,

Anna Bejrowska,

Zofia Mazerska

Publication year - 2018

Publication title -

pharmacological reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.706

H-Index - 83

eISSN - 2299-5684

pISSN - 1734-1140

DOI - 10.1016/j.pharep.2018.03.007

Subject(s) - glucuronidation , chemistry , microsome , enzyme , ugt2b7 , glucuronide , ic50 , drug metabolism , recombinant dna , non competitive inhibition , isozyme , metabolite , pharmacology , drug , biochemistry , in vitro , biology , gene

The compound 9-(2'-hydroxyethylamino)-4-methyl-1-nitroacridine (C-1748), the promising antitumor agent developed in our laboratory was determined to undergo phase I metabolic pathways. The present studies aimed to know its biotransformation with phase II enzymes - UDP-glucuronosyltransferases (UGTs) and its potential to be engaged in drug-drug interactions arising from the modulation of UGT activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research